The Open Question In McKesson’s Two New Deals

MCKYTD+33.5%SPYYTD+8.2%XLVYTD+21.1%
Analyze MCK →

For questions about this article or underlying research, email help@trefis.com.

McKesson (MCK) is spending to grow further beyond drug distribution into clinical research and home infusion. The company closed its purchase of Precision Medicine Group in early November 2026. It has also agreed to buy a minority stake in Option Care Health. You do not yet know how much of McKesson these deals touch, or what they will add.

Image from Pixabay

Precision Medicine Group Joins McKesson’s Fastest-Growing Segment

Management said Precision Medicine Group brings clinical research expertise in oncology, rare and orphan diseases, and cell and gene therapies. It also has experience running late-stage clinical trials. Management called Option Care Health the nation’s largest independent provider of home and alternate site infusion services. On McKesson’s November 4, 2026 earnings call, an analyst asked how the two businesses would fit into the company’s reporting segments. Management said the Option Care Health stake will be recorded under the equity method, in the corporate segment rather than an operating segment.

Management said Precision Medicine Group will report inside the oncology and multispecialty segment. That segment brought in $48.4 billion in fiscal 2026, accounting for 12.0% of McKesson’s revenue. Its revenue grew 31.4% that year, the fastest of any McKesson segment. Management expects the segment’s revenue to grow 20% to 24% in fiscal 2027.

What McKesson Expects The Deals To Add

Management expects Precision Medicine Group to add about $0.10 to $0.20 to adjusted earnings per diluted share in fiscal 2027. Most of it is expected in the fourth quarter. That is small beside the $45.60 to $46.40 a share McKesson now guides for the full year. By the end of the deal’s third year, management estimates it will add about $1.60 to $1.80 a share. Management did not say whether that is a yearly figure.

Those estimates cover Precision Medicine Group alone. McKesson agreed to invest about $1.4 billion for 49% of Option Care Health. Management said its current outlook leaves that deal out. The company expects the transaction to close in the first half of calendar 2027, once Option Care Health stockholders and regulators approve it. Management said the deal reflects its view that care will increasingly be delivered in lower-cost community settings, at or closer to home.

Where McKesson’s Oncology Profit Shows Precision Medicine Group First

McKesson is expected to report its fiscal third quarter in February 2027. That will be the first report to include Precision Medicine Group inside the oncology and multispecialty segment. In the second quarter, the segment’s operating profit rose 8% to $427 million. The year-earlier quarter included $51 million of net gains within The U.S. Oncology Network. Excluding those gains, management said operating profit rose 23%. For fiscal 2027 as a whole, management expects the segment’s operating profit to grow 18% to 22%. That report’s segment profit growth will include the new business for the first time. The number to watch is how much of that growth management credits to Precision Medicine Group.

It is too early to know whether these deals will pay off on the schedule management has set, and a single stock can turn on that kind of surprise.

Stop Guessing. Start Positioning.

No one can predict surprises like this one. The Trefis High Quality (HQ) Portfolio doesn’t try: it holds 30 quality stocks in equal weight, so no single surprise decides your result. Come see how it works.

See How HQ Works

Spot an error or want more like this? Tell us in 10 seconds.